Moreover, in terms of human papillomavirus (HPV), the results of a phase 3 clinical trial focusing on unresectable or metastatic head and neck cancer showed that immunotherapy had more benefit on overall survival (OS) among PD-L1 expressors with HPV-positive tumours than their counterparts with HPV-negative tumours [8]. This evidence concerns the gene CD274 and neoplasm.